View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
August 12, 2021

AI in pathologic response (PathR) assessment and patient stratification

To offset the limitations of pathologic response assessment, numerous machine learning and deep learning programmes are being explored.

By GlobalData Healthcare

The catalyst effect of Covid-19 on healthcare systems worldwide has further emphasised the need to expedite the application of digital strategies in hospitals, particularly artificial intelligence (AI) pathologic response (PathR) assessment in precision medicine and AI models for patient stratification in routine care. PathR, specifically major pathologic response (MPR), is manually determined by pathologists from tumour resection slides to elucidate the efficacious clinical endpoint (≤10% viable residual tumour) of cancer patients treated with therapy. This is a time-consuming and occasionally erroneous process that can have detrimental impacts on patients’ health outcomes due to treatment flow depending on pathological assessment.

To offset these limitations and gain more accurate metrics than can be achieved by manual evaluation, numerous machine learning (ML) and deep learning programmes are being explored as scalable, precise and reproducible approaches for patient stratification and predicting long-term outcomes. At this year’s American Society of Clinical Oncology (ASCO) conference, Owkin, a startup pioneering AI technologies for medical research and clinical development, presented the clinical utility of the first AI-based tool in predicting the genomic subtypes of pancreatic cancer from histology slides. Owkin’s ML model opens the potential to improve routine care and clinical trial efficiency through early patient molecular stratification, thereby identifying patients who respond better to specific investigative therapies.

Another leading AI vendor providing advanced platforms for clinical development at ASCO 2021 is PathAI, whose collaboration with Roche’s Genentech LCMC3 Phase II study highlighted the potential of ML in supporting pathologists to assess PathR. PathAI’s digital model analysed the pathological specimens from non-small cell lung cancer patients who had resections following neoadjuvant use of Roche’s Tecentriq (atezolizumab) and revealed a strong agreement between its ML-model assessment of MPR and its manual comparator arm (area under the receiver operating characteristic = 0.975). In addition, digitally assessed MPR was significantly associated with better disease-free survival (DFS) and overall survival (OS), while its manual comparator arm showed a non-significant trend towards better DFS and OS.

Although further data maturation of the LCMC3 trial is still required to make concrete conclusions, PathAI’s multi-faceted platform sets itself apart as a patient enrolment and candidate companion diagnostics tool generating reproducible pathology scores into clinical trial workflows. In May, PathAI raised $165m in its Series C bid to expand its clinical research capabilities. Contributing investors included Bristol Myers Squibb, Labcorp and Merck’s Global Health Innovation Fund.

Though not all were at ASCO 2021, other worthy mentions are Deep Lens, AiCure, GNS and Unlearn.AI, whose platforms also focus on identifying appropriate patients, predicting patient outcomes and streamlining the operational process of clinical trials.

While there are ample opportunities for business traction in the digital pathology market, a major limitation envisioned would be the lack of ultrafast scanners and image management systems in several hospitals worldwide. This, coupled with the willingness of pathologists to revise and adopt digitalised image analysis, could impede the market traction of digital pathology. Factors like Covid-19 and the continual rise of cancer worldwide have, however, further emphasised the need for imminent adoption of AI to improve patient stratification in routine care and clinical trials, predict outcomes and decrease histopathology turnaround time.

GlobalData forecasts from the AI in Healthcare Thematic report published in April suggest that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, up from $1.5bn in 2019. Compound annual growth rates (CAGRs) between 2019 and 2024 will be 24.6% in healthcare, 18.5% in pharma and 20.6% in medical devices.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy